MARKET

ARTV

ARTV

ARTIVA BIOTHERAPEUTICS INC
NASDAQ
4.180
-0.250
-5.64%
Closed 19:59 12/30 EST
OPEN
4.480
PREV CLOSE
4.430
HIGH
4.522
LOW
4.180
VOLUME
120.90K
TURNOVER
0
52 WEEK HIGH
11.55
52 WEEK LOW
1.470
MARKET CAP
102.60M
P/E (TTM)
-1.2879
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ARTV last week (1222-1226)?
Weekly Report · 2d ago
Wedbush Remains a Buy on Artiva Biotherapeutics, Inc. (ARTV)
TipRanks · 12/22 13:36
Weekly Report: what happened at ARTV last week (1215-1219)?
Weekly Report · 12/22 09:16
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 12/16 17:05
Artiva Biotherapeutics CEO Fred Aslan Reports Sale of Common Shares
Reuters · 12/16 02:20
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 12/15 21:06
Crude Oil Falls Over 1%; US Homebuilder Sentiment Edges Higher In December
Benzinga · 12/15 17:30
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 12/15 17:06
More
About ARTV
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.

Webull offers Artiva Biotherapeutics Inc stock information, including NASDAQ: ARTV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARTV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARTV stock methods without spending real money on the virtual paper trading platform.